{(2S)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methylamine | 407640-16-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: {(2S)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methylamine
• 英文别名: C-[(2S)-4-(5-chlorothiophen-2-ylmethyl)morpholin-2-yl]methylamine；1-{(2S)-4-[(5-Chlorothien-2-yl)methyl]morpholin-2-yl}methanamine；[(2S)-4-[(5-chlorothiophen-2-yl)methyl]morpholin-2-yl]methanamine
• CAS: 407640-16-8
• 化学式: C₁₀H₁₅ClN₂OS
• 分子量: 246.761
• InChiKey: HNEWQPPOKGJEOY-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  66.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {(2S)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methylamine 、 3-甲磺酰氨基苯乙酸 以to give the title compound (0.102 g)的产率得到N-({(2S)-4-[(5-Chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-{3-[(methylsulfonyl)amino]phenyl}acetamide
  参考文献：
  名称：

  Process for the preparation of morpholine derivatives and intermediates therefore

  摘要：

  本发明揭示了制备式（IIIA）化合物或其盐的过程。

  公开号：

  US20050222147A1

文献信息

• [EN] ANTI-INFLAMMATORY MORPHOLIN-ACETAMIDE DERIVATIVES<br/>[FR] DERIVES DE MORPHOLINE-ACETAMIDE ANTI-INFLAMMATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2003082862A1

  公开（公告）日：2003-10-09

  Certain compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 1 to 5;R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 represents hydrogen or C1-6alkyl;and salts and solvates thereof are CCR-3 antagonists and are thus indicated to be useful in therapy.

  具有以下化学式（I）的某些化合物：其中：R1代表取代或未取代的杂环烷基；Y代表-(CRnaRnb)n-；Rna和Rnb分别独立地表示氢或C1-6烷基；n为1至5的整数；R2代表未取代或取代的芳基或未取代或取代的杂环烷基；R3代表氢或C1-6烷基；其盐和溶剂合物是CCR-3拮抗剂，因此被认为在治疗中有用。
• Morpholin-acetamide derivatives for the treatment of inflammatory diseases
  申请人：——

  公开号：US20040058923A1

  公开（公告）日：2004-03-25

  Compounds of formula (I) wherein: R 1 represents C 1-16 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-6 alkynyl-Y 1 —, aryl-Y 1 —, heteroaryl-Y 1 —, aryl-(O) t -aryl-Y 1 —, aryl-(O) t -heteroaryl-Y 1 —, heteroaryl-(O) t -aryl-Y 1 —, heteroaryl-(O) t -heteroaryl-Y 1 —, C 2-6 alkenyl-Y 1 —, aryl-O—Y 1 —, heteroaryl-O—Y 1 —, C 1-16 alkyl-SO 2 —Y 1 —,M—Y 1 —,J 2 -Y 1 —, —CN or C 3-8 cycloalkyl-Y 1 — or C 3-8 cycloalkenyl-Y 1 —, which cycloalkyl or cycloalkenyl may be optionally substituted by one or more hydroxyl or C 1-16 Alkyl groups; R 2 represents hydrogen or C 1-16 alkyl; X represents ethylene or a group of formula CR e R f wherein R e and R f independently represent hydrogen or C 1-14 alkyl or R e and R f may together with the carbon atom to which they are attached form a C 3-8 cycloalkyl group; R 3 and R 4 independently represent hydrogen or C 1-14 alkyl; Z represents a bond, CO, SO 2 , CR 9 R 6 (CH 2 ) n , (CH 2 ) n CR 9 R 6 , CHR 6 (CH 2 ) n O, CHR 6 (CH 2 ) n S, CHR 6 (CH 2 ) n OCO, CHR 6 (CH 2 ) n CO, COCHR 6 (CH 2 ) n or SO 2 CHR 6 (CH 2 ) n ; n represents an integer from 0 to 4; processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases. 1

  式(I)的化合物，其中：R1代表C1-16烷基，C2-6烯基，C2-6炔基，C2-6炔基-Y1—，芳基-Y1—，杂环芳基-Y1—，芳基-(O)t-芳基-Y1—，芳基-(O)t-杂环芳基-Y1—，杂环芳基-(O)t-芳基-Y1—，杂环芳基-(O)t-杂环芳基-Y1—，C2-6烯基-Y1—，芳基-O—Y1—，杂环芳基-O—Y1—，C1-16烷基-SO2—Y1—，M—Y1—，J2-Y1—，—CN或C3-8环烷基-Y1—或C3-8环烯基-Y1—，其中环烷基或环烯基可以选择地被一个或多个羟基或C1-16烷基基团取代；R2代表氢或C1-16烷基；X代表乙烯或公式CReRf的基团，其中Re和Rf独立地代表氢或C1-14烷基，或Re和Rf可以与它们连接的碳原子一起形成C3-8环烷基基团；R3和R4独立地代表氢或C1-14烷基；Z代表键，CO，SO2，CR9R6(CH2)n，( )nCR9R6，CHR6( )nO，CHR6( )nS，CHR6( )nOCO，CHR6( )nCO，COCHR6( )n或SO2CHR6( )n；n代表一个从0到4的整数；它们的制备方法，包含它们的配方以及它们在治疗炎症性疾病中的用途。
• Compounds useful in the treatment of inflammatory diseases
  申请人：——

  公开号：US20040058907A1

  公开（公告）日：2004-03-25

  There are provided according to the invention, novel compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X a, b, and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新颖的化合物公式（I），其中R1、R2、R3、R4、R5、R6、X、a、b和Z如规范中所定义，制备它们的方法，包含它们的配方以及它们在治疗炎症性疾病方面的应用。
• [EN] COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] COMPOSES UTILES DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2002026723A1

  公开（公告）日：2002-04-04

  There are provided according to the invention, novel compounds of formula (I) wherein R?1, R2, R3, R4, R5, R6¿, X a, b, and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式，其中R1、R2、R3、R4、R5、R6、X、a、b和Z的定义如规范中所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。
• Novel compounds
  申请人：Ancliff Ann Rachael

  公开号：US20060063765A1

  公开（公告）日：2006-03-23

  Compounds of formula (I): wherein: R 1 represents substituted or unsubstituted heteroaryl; Y represents —(CR na R nb ) n —; R na and R nb are each independently hydrogen or C 1-6 alkyl; n is an integer from 0 to 5; R 2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R 3 and R 4 each independently represent hydrogen or C 1-6 alkyl; R 7 represents hydrogen or C 1-6 alkyl; R 8 represents hydrogen or C 1-6 alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.

  式（I）的化合物： 其中： R1代表取代或未取代的杂环芳基； Y代表—（CRnaRnb）n—； Rna和Rnb各自独立地代表氢或C1-6烷基； n为0到5的整数； R2代表未取代或取代的芳基或未取代或取代的杂环芳基； R3和R4各自独立地代表氢或C1-6烷基； R7代表氢或C1-6烷基； R8代表氢或C1-6烷基； 它们的盐和溶剂化物是CCR3拮抗剂，因此被认为在治疗中有用。